Consumer perspective by Walter, Rick
I will describe the international regulatory situation as well as the public
attitudes in several regions of the world (Europe, Japan, Australia, and North
America). I will introduce a selection of results from North American surveys
describing the public attitude environment, and I will then provide a brief
synopsis of the NABC environment that has developed over the past decade. I
will also attempt to draw some consistent threads among these challenged
environments and offer some suggestions for where we go from here.
I will cover the complex and rapidly changing regulatory and government
policy environment related to food biotechnology because regulatory policy in
the developed world tends to reflect the moral, ethical and cultural sentiments
of the voting public. I emphasize , however, that these are my personal
interpretations of this rapidly changing environment, not to be confused with
official government position statements.
Simply put, Europe is in a state of chaos. It has a large and ever-rising
backlog of approval submissions that are not being adequately addressed. One
of the complications is a dual approval system which governs product approvals
by the European Commission, as well as the individual member state regulatory
agencies. Product approval through this multilayered system is more onerous
than equivalent approvals in other developed nations.
The European Union (EU) has a strong and well-coordinated
antibiotechnology lobby led by Green Peace, which has attempted several
highly publicized blockades of transgenic grain shipments at European ports.
This lobby group has primarily focused on the controversial area of food
labeling. A difference of opinion exists among EU member states related to
labeling requirements. While the European Commission has stated that labeling
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mandatory labeling for all genetically engineered products, in part to erect
nontariff barriers to trade but also to reflect the vigorous negative public
sentiment. The application of these labeling policies to real-life situations may
prove to be extremely complicated. The controversy has also moved into the
retail market, and some outlets (Britain) are suggesting that they will not carry
genetically engineered foods without mandatory labeling. The European
Commission is providing U.S. $1.25 million over three years to advance public
awareness and understanding of biotechnology across Europe, but this has not
yet proven to be very successful because there are a wide variety of information
needs and a relatively small amount of available funding.
Japan has recently put into place a regulatory framework to deal with
biotechnology-derived foods. It has approved 19 products through this system
and several more are expected over the next few months. Japan has also made a
commitment to public awareness by establishing the Plant Biotechnology
Information Centre, which provides information to the media and consumers,
as well as offering seminars and a listing of product approvals around the
world. There is little coordinated antibiotechnology effort in Japan. Japanese
consumers appear to embrace the products of biotechnology more readily than
do Europeans, but it is difficult to judge consumer buying sentiments because
the regulatory system is very new and, though the products have been
approved, transgenic foods have not yet reached store shelves.
In Australia, biotechnology has always had a high level of support from the
federal government. In fact, the Commonwealth Scientific and Industrial
Research Organisation (CSIRO), the major government research group in
Australia, continues to drive much of the research agenda in that country. As is
sometimes the case in Canada, the Australian federal and state governments do
not always agree on issues. Biotechnology is no exception. There is no clear
mandate at the federal or state levels for regulatory oversight. As a result, an
informal regulatory system is being implemented without the requisite
statutory authority for enforcement. The Genetic Manipulation Advisory
Committee forms the backbone of this system, providing guidance on issues of
health and environmental safety. The Australian Food Authority approves new
food products and is now considering how to deal with biotechnology. Labeling
guidelines were recently released for comment by both Australia and New
Zealand, suggesting food labeling for health and safety or compositional or
nutritional change. A more controversial issue is the suggestion that products
that may contain more than five percent transgenic components also be labeled.
How such a requirement will be interpreted for commercial products has yet to
be determined. Most of the population appears to support the use of
biotechnology, including its use for food products. The antibiotechnology lobby
is not well organized and has not yet achieved much success. Equally important
is the poor coordination of the industrial community, placing the industry in
jeopardy if public sentiment begins to change.
North America is in an enviable position with a relatively stable regulatory
environment and the lion’s share of global product approvals. Both Canada and
the United States have similar health, safety, and environmental regulatory
oversight. Canada, however, requires pre-market notification for novel food
products (including those produced with biotechnology) while the United
States regulates foods after they have reached the market. The U.S. approval
system for some biotechnology products (those similar to previously approved
products) is being streamlined to reduce the regulatory burden and accelerate
product approvals based on extensive experience with these products. Food
labeling issues are being negotiated through the international food standards
organization Codex Alimentarius. In both Canada and the United States, an
interim labeling policy is in effect, requiring labeling when there is a health or
safety issue or when there is a nutritional or compositional change.
Interestingly, the antibiotechnology lobby has not been as successful in North
America as in Europe, but there are a few outspoken individuals and the
movement is becoming better organized. These groups provide a reality check
on our progress. While North America has some positive influences, it is
appropriate that we remain aware of these outspoken critics and their impact
on public attitudes.
To better understand public attitudes, I thought it would be useful to review
the findings of a selection of studies and public opinion polls carried out in
North America. While polls are useful in providing information on attitudes,
they are often biased by the style and content of questions, and they are poor at
providing reliable statistics on the final consumer product purchase decision.
Purchase decisions are based on a wide variety of criteria that differ from
consumer to consumer.
As the bovine somatotropin (BST) issue was in full swing in the United States
in 1994, a Task Force Report was developed to identify consumer reaction to
rBST. There was a loud and highly publicized outcry from a variety of sources
during the first few months of commercial release. This debate has continued in
some regions of the United Sttaes and small pockets of resistance are being
established in Vermont, Wisconsin, Maine, and a few other states. But despite
this outcry, the Task Force Report noted a slight increase in national milk
consumption. Labeling was embraced as the critical issue in these few regions
and continues to be debated in some state legislatures. rBST has not yet
received regulatory approval in Canada.
Thomas Hoban of North Carolina State University has developed a series of
public opinion polls since 1993. His major findings show that the U.S. public
was relatively unaware of biotechnology. Biotechnology products for health care
and agricultural plant applications appeared to have strong support. Trust and
credibility of information sources was also covered, and the results indicate that
the members of NABC rank well in both categories.
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The Decima and Optima studies carried out in 1993 and 1994 showed that
Canadians, too, were generally unfamiliar with biotechnology but that we are a
cautiously optimistic lot. Labeling of genetically engineered foods was strongly
supported in these and most other consumer polls done around the world. Here
again, the trust and credibility questions pointed to NABC members as holding
a lofty position in both categories.
A Canadian Angus Reid poll showed a slight increase in awareness,
indicating that the majority had heard of biotechnology by June 1995 but few
understood it. The results, consistent with other polls, showed that most
supported applications in plants, but there was less support for applications in
animals. As well, female respondents appeared more concerned than their male
counterparts.
The Trends survey, conducted by the Canadian Council of Grocery
Distributors in 1995, showed that the awareness of biotechnology-derived foods
was similar in both Canada and the United States, with U.S. consumers a little
better informed. Even so, more than half the respondents had heard nothing or
only a little about the topic. Half would purchase a biotechnology-derived
product that had improved taste, and three-quarters would purchase a
biotechnology-derived food product that had been developed for insect
resistance. This survey also placed the views of Canadians toward their food
into context. Their primary concerns were safety, nutrition, quality, and taste.
We are now undertaking a survey of public attitudes in Canada, the United
States, and Europe using the same questionnaire, carried out in the same time
frame. The results should help us compare attitudes in these regions and
determine if attitudes have shifted, now that food products are on the grocery
shelf.
I have given you a flavor of the regulatory situation in several nations, as well
as a brief look at the public attitudes in North America. So, what do we (the
NABC) do with this information, and where do we go from here? To begin
answering these questions, I thought it might be useful to provide a snapshot of
what the NABC meetings have accomplished to date. I am taking only a
selection of results and have interpreted them in my own words. I suppose that
the traditional disclaimer that these are the opinions of the speaker, not the
NABC management, is in order.
NABC 1, held in 1989, recommended that more discussion with the public
on research directions was in order. It also suggested that public education
programs be established, as well as mechanisms for the public to offer input
into decision making.
NABC 2 followed on this theme, recommending that consumers be
empowered to participate in product development, that public debate on
labeling issues be initiated, and that teaching materials be developed.
NABC 3 and 4 supported public discussion and dialogue, suggesting
multiparty involvement in the funding allocation process.
NABC 5 and 6 recommended focusing on the early education system (K-12)
and developing a public education plan.
NABC 7 and 8 suggested that we lead public discussion, focus on
differentiated audiences, and develop materials to raise awareness.
There are some obvious common themes among these results. As is true of
many other groups that provide recommendations, there was a recognition that
we did not have enough information and more research was required. Perhaps
there is some truth here, but it is somewhat self-serving as well. The call for
more communication was consistent, as was the focus on the education system.
Yet, each and every attempt to deal with the communication issues has resulted
in interminable discussion. We have been consistently short on deliverables. We
have left the action items to others while professing to be intimately involved in
the process. There has been no follow-up on the recommendations, no
coordinated effort to effect change, and precious little leadership from a group
that holds high levels of both public trust and credibility.
So, where do we go from here? Products of biotechnology are in the stores;
they are on our dinner plates. The products of biotechnology are now a reality
and consumers continue to be poorly informed at best, possibly even unaware.
It is our combined responsibility to make them aware. It is our combined
responsibility to get the message of food biotechnology out. It is our combined
responsibility to take the leadership position in this communications challenge.
Having been involved in the public information game since the late 1980s, I
am increasingly frustrated with those who remain focused solely on the
collection of information and the academic study of issues. I think it is
interesting to consider the hundreds of thousands of dollars that this group
alone has spent during the past decade, going to these meetings to discuss the
issues and to make recommendations on communication with the public. I
suppose it is appropriate, considering the audience, to ask, Where is the beef? It
is time that we move beyond the abstract to the practical by building on the
knowledge we have gained and applying it to concrete communication
activities. We must close the ever-widening information gap that exists between
science and the consuming public.
To initiate this shift in our actions, we can jointly compile a list of activities
that involve the public and the educational system. We can combine the efforts
of individual organizations into coordinated programs. We can identify gaps
where our activities have had little impact and develop new activities to address
those gaps. And finally, we can assign both human and financial resources to
support these activities. We have not yet been effective in influencing public
awareness, either on a community or an individual level. Perhaps it is time to
change the focus of this group to meet the challenged environment of low
public awareness. One Canadian organization attempting to address this gap is
the Food Biotechnology Communication Network (FBCN), which represents
consumer, farm, industry, and government organizations and provides
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information on food biotechnology. Two activities which the Canadian
biotechnology community (including FBCN) are now developing are a
communication strategy and an issues/crisis management plan. These activities
identify and assign both responsibilities and resources. The NABC has an
opportunity to undertake a similar role, but this will require significant change.
One scenario which I propose to implement such a change comes in four
phases: First, we form a group to develop a communications strategy with input
from the NABC members (possibly in conjunction with the FBCN), including
stated objectives, target audiences, key messages and messengers, and activities
that are targeted and timely. In phase two, we each identify how our own
organization will become involved in meeting the deliverables outlined in the
strategy and make this known to the NABC and other members. Then, we
jointly initiate the strategy and the activities that we have identified. Finally, the
NABC monitors the activities and, together, we evaluate our progress at each
future NABC meeting, offering a reality check on progress made. This action
plan would move us from talking among ourselves at each of these annual
NABC meetings to instituting real change in public attitudes.
Today we have looked at the international regulatory environment. We have
touched on the public attitudes environment, and we have reviewed the self-
proscribed challenges in the NABC environment over the past decade.
Continued chat among interested stakeholders is no longer suitable. For ten
years, we have been hesitant to take up the gauntlet and face our most
challenging environment, public awareness. We have an opportunity, over the
next two days, to institute a process that will form an action plan and finally
begin the implementation process. For once, let’s meet this challenge head-on.
Let’s coordinate our efforts and effect real change.
________________
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